The Fast Track designation may expedite development of PH10 for treatment of major depressive disorder in adults SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 6, 2022-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for

Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov.

Preclinical data in "gold standard" MPTP non-human primate model of Parkinson's disease show significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov.

PALISADE-2 Phase 3 trial with PH94B in social anxiety disorder restart preparations underway after independent interim analysis recommends study continue as planned Preliminary analysis of nearly 400 subjects in the final data set for the PALISADE Open Label Study demonstrates robust functional

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 4, 2022-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous

CEO Shawn Singh to lead discussion on the future of mental health solutions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,

Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen’s Board of Directors the option to implement a future reverse stock split of the Company’s issued and outstanding common stock, if necessary to maintain the Company’s listing on the Nasdaq Capital Market, and

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 6, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 3, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that